Satralizumab + Placebo
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Neuromyelitis Optica (NMO)
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Trial Timeline
Aug 5, 2014 → Jan 31, 2022
NCT ID
NCT02073279About Satralizumab + Placebo
Satralizumab + Placebo is a phase 3 stage product being developed by Chugai Pharmaceutical for Neuromyelitis Optica (NMO). The current trial status is completed. This product is registered under clinical trial identifier NCT02073279. Target conditions include Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD).
What happened to similar drugs?
2 of 5 similar drugs in Neuromyelitis Optica (NMO) were approved
Approved (2) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02073279 | Phase 3 | Completed |
Competing Products
8 competing products in Neuromyelitis Optica (NMO)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab 120 mg | Chugai Pharmaceutical | Approved | 35 |
| Satralizumab + Placebo + Baseline Treatment | Chugai Pharmaceutical | Phase 3 | 40 |
| satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids | Roche | Phase 3 | 40 |
| Satralizumab | Roche | Phase 3 | 47 |
| UPLIZNA | Amgen | Pre-clinical | 33 |
| Inebilizumab | Amgen | Phase 2 | 42 |
| Inebilizumab | Amgen | Approved | 47 |
| intravenous methylprednisolone | Brain Biotech | Pre-clinical | 23 |